- GlobeNewswire•5 days agoMyriad’s BRACAnalysis CDx® Test Successfully Identified Metastatic Breast Cancer Patients with Improved Outcomes from AstraZeneca's PARP Inhibitor, Olaparib
SALT LAKE CITY, Feb. 17, 2017-- Myriad Genetics, Inc., a leader in molecular diagnostics and personalized medicine, today announced new findings from the OlympiAD study that show its BRACAnalysis CDx ® ...
- GlobeNewswire•5 days agoMyriad’s Prolaris® Test Significantly Improves the Risk Classification for One Third of Men Diagnosed with Localized Prostate Cancer
SALT LAKE CITY, Feb. 17, 2017-- Myriad Genetics, Inc., a global leader in personalized medicine, today announced new data demonstrating the utility of the Prolaris ® test to more accurately classify mortality ...
- Motley Fool•8 days ago
A strong full-year 2016 earnings report and 2017 guidance demonstrate that Invitae is no longer a concept story.
MYGN : Summary for Myriad Genetics, Inc. - Yahoo Finance
Myriad Genetics, Inc. (MYGN)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
|Bid||15.35 x 100|
|Ask||19.36 x 600|
|Day's Range||18.49 - 19.13|
|52 Week Range||15.15 - 39.74|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||21.56|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|